Bridget Hoyt

home / authors / bridget-hoyt

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at bhoyt@mjhlifesciences.com.

Articles

Proactive Onco-Coaching Linked to Higher OS in mRCC

Bridget Hoyt

February 18th 2025

Proactive onco-coaching did not improve QOL but was associated with improved OS in patients with metastatic renal cell carcinoma receiving TKIs and ICIs.

Graphic of care providers, patients, and families conversing near large computers and health charts

Digital Health Tool Helps Patients With Prostate Cancer During Consultations

Bridget Hoyt

February 14th 2025

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

woman in front of a blue background with dark hair

Common Adverse Events With Trastuzumab Deruxtecan for Breast Cancer

Bridget Hoyt

February 4th 2025

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.

test tubes, one of which is being held by a person with a white lab coat

22% of Community Providers Reported Biomarker Testing in Gastric/GEJ Cancers

Bridget Hoyt

January 24th 2025

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing results for treatment decision-making.

green background with blue text indicating FDA and green text indicating approved with a green checkmark

FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS

Bridget Hoyt

January 24th 2025

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.

woman wearing a white tank top doing resistance exercise with assistance

Dexamethasone Plus Physical Activity May Reduce Cancer-Related Fatigue

Bridget Hoyt

January 22nd 2025

Combining aerobic and resistance-based physical activity with dexamethasone may improve quality of life and reduce the effects of fatigue.

light blue background with a white outline indicating the reproductive system

Drug Toxicity May Drive Early Niraparib Discontinuation in Ovarian Cancer

Bridget Hoyt

January 16th 2025

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized starting doses, may improve patient outcomes.

<1 2 3